Medication info
Esora Tablet 20 mg (Esomeprazole Magnesium Dihydrate)

Esora Tablet 20 mg (Esomeprazole Magnesium Dihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Dihydrate›21.69mg / 1 tablet
Manufacturer / importer
Nexpharm Korea Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets/Alu-Alu×2)
Approval status
Active

MFDS item code 201508280 · Approved 2015.12.15 · Insurance code 662503310

Summary

Main use
Treatment of acid-related disorders (reflux, ulcers, etc.), Helicobacter pylori eradication, and gastrointestinal disorders caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed dosing is not recommended for control of persistent symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer 20 mg of this medicine with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with use of nonsteroidal anti-inflammatory drugs (nonselective and selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg per day should be divided into 2 doses. 6) Maintenance therapy after induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks after induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous administration. 4. Renal impairment No dosage adjustment is necessary. Since there is limited experience in patients with severe renal impairment, administer with caution. 5. Hepatic impairment No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this medicine. 6. Elderly patients No dosage adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed dosing is not recommended for control of persistent symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
Nexpharm Korea Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (reflux, ulcers, etc.), Helicobacter pylori eradication, and gastrointestinal disorders caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • Helicobacter pylori-positive duodenal ulcer
  • peptic ulcer
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
  • recurrent gastric ulcer bleeding
View approved original text

This medication is used in the treatment of gastroesophageal reflux disease and erosive esophagitis, and for long-term maintenance therapy to prevent recurrences in patients with esophagitis. It is also effective for the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection. It is applicable for the treatment and prevention of gastric and duodenal ulcers associated with upper gastrointestinal symptoms occurring due to the use of non-steroidal anti-inflammatory drugs. It is used for maintenance therapy to prevent recurrence of bleeding from gastric ulcers or duodenal ulcers and also for the treatment of Zollinger-Ellison syndrome. Overall, it is utilized to improve various symptoms and diseases associated with gastrointestinal disorders.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed dosing is not recommended for control of persistent symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer 20 mg of this medicine with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with use of nonsteroidal anti-inflammatory drugs (nonselective and selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg daily. Doses greater than 80 mg per day should be divided into 2 doses. 6) Maintenance therapy after induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks after induction of prevention of rebleeding due to gastric or duodenal ulcers by intravenous administration. 4. Renal impairment No dosage adjustment is necessary. Since there is limited experience in patients with severe renal impairment, administer with caution. 5. Hepatic impairment No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this medicine. 6. Elderly patients No dosage adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed dosing is not recommended for control of persistent symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medication should not be administered to patients with known specific allergic reactions. For instance, if there is a hypersensitivity to this medication or its components, or if there was a history of allergy to benzimidazole derivatives. Additionally, this medication may cause hypersensitivity reactions when used in combination with certain antibiotics, so patients with allergies to penicillin or macrolide antibiotics should exercise caution. Rarely, various side effects such as blood disorders, allergic reactions, hypomagnesemia may occur during the use of this medication, so if any unusual symptoms arise, immediate consultation with a physician should be sought. It is essential to undergo regular health check-ups during long-term use, particularly for those taking the medication for more than one year; regular blood tests, including magnesium levels, should be conducted. Since this medication suppresses gastric acid, it may promote bacterial growth in the stomach, so if diarrhea or symptoms of gastrointestinal infection persist, it should be reported to healthcare personnel. Also, patients with osteoporosis or those at risk of fractures may have an increased risk of fractures during long-term use of this medication, requiring appropriate monitoring, including bone density testing. This medication may interact with certain other drugs, therefore, current medications must be disclosed to a physician or pharmacist. Pregnant or breastfeeding women should consult with healthcare personnel before taking this medication, and it is advisable to avoid its use while breastfeeding. In case of overdose, there are no specific antidotes, and symptomatic treatment should be provided; keep the medication out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, xerostomia, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, pruritus, rash, urticaria, hair loss, photosensitivity, erythema multiforme, skin and mucous membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, Riel syndrome, acute generalized exanthematous pustulosis, eosinophilia, drug reaction with systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, substernal chest pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid enlargement, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased gastrin in the blood, tongue disorders, tongue edema, ulcerative stomatitis, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, elevated ALT, elevated AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, aggravated arthritis, arthropathy, convulsions, fibromyalgia, hernia, rheumatoid polymyalgia, loss of appetite, apathy, increased appetite, confusion, aggravated depression, hypertonia, sensory impairment, erectile dysfunction, insomnia, migraine, aggravated migraine, sleep disorder, tremor, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, aggravated asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal pruritus, erythematous rash, papular rash, otitis media, abnormal olfaction, loss of taste, taste distortion, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp, mucosal discoloration, fracture, rhabdomyolysis, myalgia, weakness, elevated creatine kinase, increased myoglobin in the blood, increased myoglobin in urine, cutaneous lupus erythematosus, systemic lupus erythematosus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets/Alu-Alu×2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.